ZUSDURI

Launch

mitomycin

NDAINTRAVESICALPOWDER
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
8/100
Clinical Trials
8

Clinical Trials (5)

NCT03844256Phase 1/2Recruiting

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Started Jan 2019
50 enrolled
Urinary Bladder CancerInvasive Bladder Cancer
NCT02701088Phase 2Active Not Recruiting

Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life

Started Dec 2015
71 enrolled
Locally Advanced Anal Canal Cancer
NCT01621217Phase 1Completed

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Started Jun 2012
21 enrolled
Locally Advanced Cancer in the Anal Region
NCT01167725Phase 3Terminated

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Started Aug 2010
340 enrolled
Colorectal Cancer
NCT00892398N/ACompleted

Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab

Started Mar 2009
242 enrolled
Glaucoma

Loss of Exclusivity

LOE Date
Jan 20, 2031
59 months away
Patent Expiry
Jan 20, 2031
Exclusivity Expiry
Jun 12, 2028

Patent Records (4)

Patent #ExpiryTypeUse Code
10039832
Jan 20, 2031
U-4256
12440568
Jan 20, 2031
U-4256
9040074
Jan 20, 2031
Product
U-4256
9950069
Jan 20, 2031
Product
U-4256